Positive treatment results for Buvidal® in fentanyl users presented at the ASAM 50th Annual Conference
Phase 3 post-hoc analysis indicates less fentanyl and overall illicit opioid use for weekly/monthly buprenorphine depots versus daily standard treatment in a difficult to treat patient population Lund, Sweden — 6 April 2019 — Camurus announces positive post-hoc analyses results from the randomized, double-blind, double-dummy Phase 3 study of CAM2038 (Buvidal®, buprenorphine prolonged-release solution for subcutaneous injection) for the treatment of opioid dependent patients with evidence of fentanyl use prior to treatment initiation. The results of the post-hoc analyses, consistent